External reports (aggregated public sources), Value Investors Club

Value Investors Club (VIC)

External reports (aggregated public sources)

Value Investors Club

Equity Bottom-Up

<ul><li>Cardinal Health is a wholesale drug and medical supplies distributor competing in the industry</li><li>The company is focusing on transitioning to higher-margin services for growth and profitability</li><li>Strong performance under CEO Jason Hollar with double-digit EPS growth, share repurchases, and three-year growth targets, despite challenges like generic price fluctuations</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

Cardinal Health is a wholesale drug and medical supplies distributor competing in the industryThe company is focusing on transitioning to higher-margin services for growth and profitabilityStrong performance under CEO Jason Hollar with double-digit EPS growth, share repurchases, and three-year growth targets, despite challenges like generic price fluctuationsThis content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Cardinal Health Inc (CAH) - Monday, Oct 14, 2024

Covering IPOs, Healthcare and Technology Stocks

Andrei Zakharov

Equity Capital Markets

<ul>
<li>Heartflow Inc., a commercial-stage medical technology company that has pioneered the use of software and AI for diagnosing and managing CAD, is expected to IPO this week.</li>
<li>Heartflow is marketing the sale of ~16.7M shares at $17-$18 per share in upsized initial public offering in the United States.</li>
<li>I believe current IPO valuation range appears to capture much of the near- to mid-term upside potential. Moreover, I’m concerned about the lack of profitability and mounting losses.</li>
</ul>


Heartflow Inc., a commercial-stage medical technology company that has pioneered the use of software and AI for diagnosing and managing CAD, is expected to IPO this week.
Heartflow is marketing the sale of ~16.7M shares at $17-$18 per share in upsized initial public offering in the United States.
I believe current IPO valuation range appears to capture much of the near- to mid-term upside potential. Moreover, I’m concerned about the lack of profitability and mounting losses.


Heartflow IPO: Mounting Losses, ~99% Revenue Concentration From a Single Product

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul><li>Cardinal Health, Inc. reported strong financial and operational results for the first quarter of fiscal year 2025, primarily driven by its Pharmaceutical and Specialty Solutions segment.</li><li>CEO Jason Hollar highlighted the company's effective management amidst a customer transition in its largest business segment, which still achieved a 16% growth in segment profit.</li><li>The demand across various pharmaceutical categories, notably specialty and consumer health, played a significant role in this growth.</li></ul>

Cardinal Health, Inc. reported strong financial and operational results for the first quarter of fiscal year 2025, primarily driven by its Pharmaceutical and Specialty Solutions segment.CEO Jason Hollar highlighted the company's effective management amidst a customer transition in its largest business segment, which still achieved a 16% growth in segment profit.The demand across various pharmaceutical categories, notably specialty and consumer health, played a significant role in this growth.

Cardinal Health: Can Its Strategic Acquisitions & Improving Market Position Be A Sustainable Growth Accelerator?  - Major Drivers

<ul><li>Cardinal Health Incorporated has shown a remarkable year with strong operational performance, achieving a considerable improvement in key financial metrics as highlighted in their Fourth Quarter FY 2024 Earnings.</li><li>During the fiscal year 2024, Cardinal Health reported striking growth in earnings per share (EPS), marking a 29% increase in both the fourth quarter and for the entire year.</li><li>The substantial growth in EPS throughout FY 2024 to $7.53 indicates a positive trajectory exceeding the company’s initial guidance significantly.</li></ul>

Cardinal Health Incorporated has shown a remarkable year with strong operational performance, achieving a considerable improvement in key financial metrics as highlighted in their Fourth Quarter FY 2024 Earnings.During the fiscal year 2024, Cardinal Health reported striking growth in earnings per share (EPS), marking a 29% increase in both the fourth quarter and for the entire year.The substantial growth in EPS throughout FY 2024 to $7.53 indicates a positive trajectory exceeding the company’s initial guidance significantly.

Cardinal Health Inc.: How Are They Achieving Specialty Business Growth Despite Nonrenewal Challenges! - Major Drivers

<ul><li>Cardinal Health, Inc., a provider of healthcare products and services, reported its Q3 FY2024 financial performance.</li><li>The quarter displayed broad-based growth as the company worked on its four strategic priorities, eventually leading to growth and raised outlook for the fiscal year '24.</li><li>The pharmaceutical and specialty solutions business showed strong growth, riding on ongoing stability in pharmaceutical demand.</li></ul>

Cardinal Health, Inc., a provider of healthcare products and services, reported its Q3 FY2024 financial performance.The quarter displayed broad-based growth as the company worked on its four strategic priorities, eventually leading to growth and raised outlook for the fiscal year '24.The pharmaceutical and specialty solutions business showed strong growth, riding on ongoing stability in pharmaceutical demand.

Cardinal Health: Deep-Rooted Market Relationships & Competitive Edge! - Major Drivers

United States

Cardinal Health, Inc. provides complementary products and services to healthcare providers and manufacturers.  The Company's services include pharmaceutical distribution, health-care product manufacturing, distribution and consulting services, drug delivery systems development, pharmaceutical packaging, automated dispensing systems manufacturing, and retail pharmacy franchising.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cardinal Health (CAH US)

Cardinal Health Inc (CAH) - Monday, Oct 14, 2024

Strong performance under CEO Jason Hollar with double-digit EPS growth, share repurchases, and three-year growth targets, despite challenges like...

Value Investors Club (VIC)

Heartflow IPO: Mounting Losses, ~99% Revenue Concentration From a Single Product

Heartflow Inc., a provider of AI-powered scalable software platform for diagnosing and managing CAD, set to IPO this week. In my insight, I...

Andrei Zakharov

Cardinal Health: Can Its Strategic Acquisitions & Improving Market Position Be A Sustainable Growth Accelerator? - Major Drivers

Cardinal Health, Inc. reported strong financial and operational results for the first quarter of fiscal year 2025, primarily driven by its...

Baptista Research

Cardinal Health Inc.: How Are They Achieving Specialty Business Growth Despite Nonrenewal Challenges! - Major Drivers

Cardinal Health Incorporated has shown a remarkable year with strong operational performance, achieving a considerable improvement in key...

Baptista Research

Cardinal Health: Deep-Rooted Market Relationships & Competitive Edge! - Major Drivers

Cardinal Health, Inc., a provider of healthcare products and services, reported its Q3 FY2024 financial performance. The quarter displayed...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Cardinal Health Inc (CAH) - Monday, Oct 14, 2024

Strong performance under CEO Jason Hollar with double-digit EPS growth, share repurchases, and three-year growth targets, despite challenges like...

Value Investors Club (VIC)

Heartflow IPO: Mounting Losses, ~99% Revenue Concentration From a Single Product

​Heartflow Inc., a provider of AI-powered scalable software platform for diagnosing and managing CAD, set to IPO this week. In my insight, I...

Andrei Zakharov

Cardinal Health: Can Its Strategic Acquisitions & Improving Market Position Be A Sustainable Growth Accelerator? - Major Drivers

Cardinal Health, Inc. reported strong financial and operational results for the first quarter of fiscal year 2025, primarily driven by its...

Baptista Research

Cardinal Health Inc.: How Are They Achieving Specialty Business Growth Despite Nonrenewal Challenges! - Major Drivers

Cardinal Health Incorporated has shown a remarkable year with strong operational performance, achieving a considerable improvement in key...

Baptista Research

Cardinal Health: Deep-Rooted Market Relationships & Competitive Edge! - Major Drivers

Cardinal Health, Inc., a provider of healthcare products and services, reported its Q3 FY2024 financial performance. The quarter displayed...

Baptista Research

Heartflow Inc., a provider of AI-powered scalable software platform for diagnosing and managing CAD, set to IPO this week. In my insight, I...